Indications and Purposes
| 1 Indications And Usage Crysvita Is A Fibroblast Growth Factor 23 (Fgf23) Blocking Antibody Indicated For: The Treatment Of X-Linked Hypophosphatemia (Xlh) In Adult And Pediatric Patients 6 Months Of Age And Older. ( 1.1 ) The Treatment Of Fgf23-Related Hypophosphatemia In Tumor-Induced Osteomalacia (Tio) Associated With Phosphaturic Mesenchymal Tumors That Cannot Be Curatively Resected Or Localized In Adult And Pediatric Patients 2 Years Of Age And Older. ( 1.2 ) 1.1 X-Linked Hypophosphatemia Crysvita Is Indicated For The Treatment Of X-Linked Hypophosphatemia (Xlh) In Adult And Pediatric Patients 6 Months Of Age And Older. 1.2 Tumor-Induced Osteomalacia Crysvita Is Indicated For The Treatment Of Fgf23-Related Hypophosphatemia In Tumor-Induced Osteomalacia (Tio) Associated With Phosphaturic Mesenchymal Tumors That Cannot Be Curatively Resected Or Localized In Adult And Pediatric Patients 2 Years Of Age And Older. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Burosumab |